Genoray Co. Ltd
Genoray Co., Ltd. engages in the research, development, manufacture, and sale of medical and dental x-ray devices in South Korea. It offers C-ARM and mammography medical x-ray devices; and 2D, 3D, ENT, and IOS/IOX dental x-ray devices, as well as related maintenance and repair services. The company also exports its products to approximately 80 countries worldwide. Genoray Co., Ltd. was founded in… Read more
Genoray Co. Ltd - Asset Resilience Ratio
Genoray Co. Ltd (122310) has an Asset Resilience Ratio of 0.03% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Genoray Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Genoray Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩35.60 Million | 0.03% |
| Total Liquid Assets | ₩35.60 Million | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Genoray Co. Ltd maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Genoray Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Genoray Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
|
Bionet
TWO:1784 |
Diagnostics & Research | 38.62% |
|
Cytogen Inc
KQ:217330 |
Diagnostics & Research | 39.93% |
|
U2Bio Co., Ltd.
KQ:221800 |
Diagnostics & Research | 68.57% |
Annual Asset Resilience Ratio for Genoray Co. Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Genoray Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 14.90% | ₩18.39 Billion | ₩123.44 Billion | +2.91pp |
| 2023-12-31 | 11.98% | ₩14.89 Billion | ₩124.27 Billion | -11.31pp |
| 2022-12-31 | 23.29% | ₩24.74 Billion | ₩106.20 Billion | -8.99pp |
| 2021-12-31 | 32.29% | ₩32.08 Billion | ₩99.37 Billion | +0.70pp |
| 2020-12-31 | 31.59% | ₩27.09 Billion | ₩85.74 Billion | +0.20pp |
| 2019-12-31 | 31.39% | ₩24.64 Billion | ₩78.52 Billion | +2.54pp |
| 2018-12-31 | 28.85% | ₩16.86 Billion | ₩58.44 Billion | +15.72pp |
| 2017-12-31 | 13.13% | ₩4.95 Billion | ₩37.73 Billion | -0.45pp |
| 2016-12-31 | 13.58% | ₩4.53 Billion | ₩33.39 Billion | -- |